Wire · regulatory
FDA wants to remove cholesterol drug from market
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 19 November 2026 · Fusion42 review
The FDA intends to withdraw approval of Salerno Pharmaceuticals' liquid statin drug FloLipid due to repeated non-compliance with mandatory reporting requirements, potentially removing the drug from the U.S. market.
This Wire brief sits within Fusion42's coverage of Drug Discovery, and 3 sources have reported it.
◆ ◆ The Wire takeaway
You must prepare for tighter FDA compliance as failure to keep up with reporting can lead to sudden market exit. Drug founders need to prioritise regulatory deadlines to secure market access and avoid costly removals.
◆ Coverage
3 sources · 18 Nov 2026
◆ Related on Wire
◆ Topics